Effective pain control is essential for optimal care of patients after trauma and surgery. 1 2 Thus, in most intensive care units (ICU) analgesia as well as sedation is provided to enable the patient to tolerate the tracheal tube and mechanical ventilation. Accumulation of long-acting opioids occurs, and continuous assessment and adjustment of dose to meet the changing need is necessary. In addition, emergence from analgesia and sedation in patients with impaired liver or kidney function may be signi®cantly prolonged. An intermittent neurological assessment of patients with brain injury may be dif®cult As remifentanil is metabolized by non-speci®c esterases, it is eliminated very quickly and independently of liver or kidney function. The context-sensitive half time is 3±4 min and is independent of the duration of infusion. 3 The present investigation was performed to study the effects of remifentanil administered in combination with a hypnotic to provide analgesia and sedation in ICU patients. We wanted to investigate if it was possible to: (1) provide adequate analgesia with remifentanil and (2) achieve complete emergence from analgesia and sedation (neurological recovery) within minutes after termination of the remifentanil infusion. As morphine and fentanyl 4 have unfavourable pharmacokinetics if administered as a continuous infusion, we chose sufentanil for comparison with remifentanil. Sufentanil has a context-sensitive half time of 34 min after 4 h infusion. 3 Since its introduction in the 1980s, sufentanil has been frequently used for postoperative analgesia and sedation in ICU patients.
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Methods
After approval by the Ethics Committee and written informed consent from the patient (elective surgery) or relatives (trauma), 21 mechanically ventilated patients requiring analgesia and sedation were included in the study. Indications for mechanical ventilation were respiratory failure after major trauma or operation, or compromised airways because of infection or postoperative swelling. The design of the investigation was double blind and prospective. Patients were assigned randomly to group R (remifentanil) or S (sufentanil) using a computerized allocating schedule. Exclusion criteria were: age <18 yr, pregnancy, neurological disease (history of apoplectic stroke, severe head trauma), coronary artery disease CCS III-IV (Canadian Cardiovascular Society), congestive heart failure NYHA III-IV (New York Heart Association), unstable haemodynamics (patients requiring >4 units of blood or 2 litre of cristalloids or colloids in 12 h in addition to basic¯uid replacement; patients requiring cardiocirculatory support of dopamine >3 mg kg ±1 min ±1 or norepinephrine >0.1 mg kg ±1 min ±1 ), intolerance to one of the used drugs, hepatic or renal abnormalities (serum cholinesterase <10 000 nkat litre ±1 , serum bilirubin >24 mmol litre ±1 ; serum creatinine >100 mmol litre ±1 ). Patients received either balanced anaesthesia with iso¯urane, nitrous oxide, and fentanyl in the operating theatre (elective surgery) or a fentanyl/midazolam anaesthesia in the emergency room (trauma). On transfer to and after arrival at the ICU, all patients received midazolam and fentanyl before the trial was started. Details of the patients and the amounts of fentanyl and midazolam administered before the onset of the trial are listed in Table 1 . For every patient, the study started during the ®rst 24 h of their study on the ICU.
To evaluate the degree of sedation, we used the Ramsay score. 9 In order to assess pain, we used a simpli®ed pain score, which allowed the sedated patient (Ramsay score 2±5) to differentiate between three levels of pain: (1) nodding the head for`I feel pain', (2) shaking the head for`I don't feel pain', and (3) no head movement because of marked sedation (Ramsay >3). As far as possible, under the clinical conditions of a critically ill patient requiring high amounts both sedative and analgesic drugs, we tried to differentiate between insuf®cient sedation and incomplete pain relief. Propofol was administered with an initial dose of 2 mg kg ±1 h ±1 as the sedative component. In addition, patients initially received either remifentanil 5 mg kg ±1 h ±1 or sufentanil 0.5 mg kg ±1 h ±1 . The aim was to achieve a Ramsay score adapted to the patient's individual demand ranging from 2 (e.g. weaning from arti®cial ventilation) to 5 (e.g. in case of severe respiratory failure) together with complete pain relief. In case of pain or inadequate sedation, the dose of the drugs was adjusted stepwise according to the following procedure.
In case of inadequate sedation, the propofol infusion was increased to 2.5 mg kg ±1 h ±1 and if sedation remained insuf®cient 15 min after the ®rst adjustment, the propofol infusion was increased to 3.0 mg kg ±1 h ±1 and likewise increased, if necessary, every 15 min. To facilitate procedures such as washing, punctures, etc., additional boli of propofol (20±50 mg) were permitted. When sedation was excessive (Ramsay score 6), the infusion of propofol was decreased by 0. 5 The degree of sedation and the pain score was assessed every 2 h and the dose of propofol and/or the opioid was adjusted accordingly. In case of inadequate sedation (Ramsay score <2), or spontaneous complaint of pain between scheduled observation intervals, drug doses were adjusted as described.
Patients were ventilated to normocapnia (mandatory minute ventilation by respirator EVITA 2±4, Draeger Werke AG, Lu Èbeck, Germany).
Measurements
The continuous analgesic and sedative medication was temporarily stopped after 24 h. Immediately before and 10 and 30 min after the following parameters were determined: systolic (SAP) and diastolic (DAP) invasive arterial pressure, heart rate, arterial carbon dioxide, oxygen and pH, spontaneous ventilation as a percentage of respiratory minute volume, degree of sedation, and pain score. Drug administration was recommenced after the 30 min measurement or immediately (together with a bolus of propofol) if the patient complained of pain or had a Ramsay score of <2.
The values for the sedation score and fraction of spontaneous ventilation are expressed as median (25th, 75th percentile), values for the pain score are expressed as frequencies. The data for arterial pressure, heart rate, pH, arterial carbon dioxide and oxygen are reported as their mean (SD). The Wilcoxon signed-ranks test was used to determine the effect of remifentanil (0, 10 min) and Friedman test followed by Dunn's method was conducted to determine the effect of sufentanil (0, 10, 30 min) on HR, SAP, DAP, pH, Pa CO 2 , degree of sedation, pain score and fraction of spontaneous ventilation. The Mann±Whitney Utest was used to evaluate differences between groups (0, 10 min). Statistical analysis was performed with the software package Sigma Stat for Windows Version 2.03 (SPSS Inc., USA). P<0.05 was considered signi®cant for all tests.
Results
Of the 21 patients recruited, 20 completed the study. One patient underwent emergency surgery during the measurements (patient no. 14; sufentanil) and was excluded from the study. There were no statistically signi®cant differences in patient characteristics between the groups ( Immediately before terminating the continuous infusion, there was no difference between groups with respect to the degree of sedation as indicated by the Ramsay score (median: 3 in both groups, Fig. 1 ). During the ®rst 10 min after stopping the administration of the infusions, in the sufentanil group the Ramsay score (median) remained unchanged (3) compared with the control and decreased signi®cantly (2, P<0.05), 30 min after terminating the infusion. In the remifentanil group the Ramsay score signi®cantly (P=0.002) decreased from 3 (control) to 1.5, 10 min after stopping the analgesic and sedative infusion. The difference between groups at the 10-min time point was signi®cant (P=0.015 for remifentanil versus sufentanil, Fig.  1 ). During the following 20 min of the scheduled observation period, nine patients in the remifentanil group emerged from analgesia and sedation (Ramsay score <2) and measurements were stopped and infusion was recommenced. Subsequently, valid data are available only for one patient in the remifentanil group at 30 min. In the sufentanil group, the continuous infusion had to be restarted only once before completing the 30 min evaluation interval.
With respect to the pain scores, no signi®cant differences between the investigated groups immediately before stopping the infusion were seen. Ten minutes after terminating the infusion, six patients in the remifentanil group complained of pain, three patients denied pain and one patient did not react because of deep sedation; in the sufentanil group all patients negated pain (n=6) or did not react because of deep sedation (n=4) (P=0.055 for remifentanil 0 min versus remifentanil 10 min; P=0.014 for remifentanil 10 min vs sufentanil 10 min; Table 2 ). In the sufentanil group the ®rst pain complaint was observed after 30 min (one patient; Table 2 5 .04 (0.81) kPa). After 24 h of continuous analgesic and sedative infusion, the incidence of spontaneous ventilation in the remifentanil group increased from 23 to 56% within the ®rst 10 min after terminating the infusion. In the sufentanil group the incidence remained unchanged (22%) during the ®rst 10 min and increased to 53% 30 min after terminating the infusion (not signi®cant). Table 2 Number of patients complaining of pain after terminating a remifentanil/propofol or sufentanil/propofol infusion. Data are expressed as frequencies. *P=0.014 for remifentanil (10 min) vs sufentanil (10 min). No complete data exist for the remifentanil group and the sufentanil group 30 min after terminating the continuous administration because nine patients in the remifentanil group and one patient in the sufentanil recovered within 10±20 min Mean systolic and diastolic invasive arterial pressure signi®cantly increased in the remifentanil group 10 min after terminating infusion compared with baseline values (SAP P=0.002, DAP P=0.002) and were signi®cantly elevated compared with the values obtained in the sufentanil group (SAP P=0.002, DAP: P=0.013). In the sufentanil group, mean systolic and diastolic arterial pressure increased signi®cantly 30 min after discontinuing the infusion (SAP: P<0.05; DAP: P<0.05, values shown in Table 3 ). No signi®cant changes in heart rates were observed in or between groups.
Discussion
In our investigation we studied the feasibility of providing analgesia and sedation for ICU patients with continuous administration of either propofol/remifentanil or propofol/ sufentanil and the time to neurological recovery after discontinuing the analgesic and sedative medication. We chose a 24 h period of study to be sure that any effects of sedative or analgesic drugs used before the start of our investigation would no longer be of signi®cance.
We were aware of the dif®culty of separating sedation and analgesia in an intubated and deeply sedated patient. Another major problem of our study was differentiating between the effects of propofol and the opioids, as both drugs possess sedative qualities and act synergistically. Using a ®xed dose of propofol, the comparison between groups would have been possible under standardized conditions. However, with administration of a ®xed high propofol dose, suf®cient for all patients, the dose of the opioid would have to be reduced to such a degree that emergence from analgesia-sedation would mainly re¯ect emergence from propofol sedation and differences between the duration of effect of the opioids would have been concealed. On the other hand, some patients clearly had no pain during the study, but were anxious and agitated (Ramsay 1) . Increasing the dose of the analgesic would not have changed this state. These patients would have suffered discomfort without a deeper degree of sedation. Therefore, the study design had to permit an increase of the dose of propofol because of ethical considerations.
Remifentanil has previously been proven to be effective in postoperative pain management after abdominal, spine and thoracic surgery or joint replacement using a mean dose of 6 mg kg ±1 h ±1 . 10 It is well known that the amount of analgesics required by ICU patients is lower than the dose necessary to provide analgesia during surgery. Nevertheless, the initial dose of 5 mg kg ±1 h ±1 in our study was not suf®cient and had to be increased in most of the patients. The mean remifentanil dose ®nally required by our patients (10.6 mg kg ±1 h ±1 ) has been reported to provide adequate analgesia during several surgical procedures.
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By contrast, compared with data published by other authors, the mean sufentanil dose required by the patients in our study (0.5 mg kg ±1 h ±1 ) was rather low. 5 8 Wappler and colleagues 8 used 0.4±1.5 mg kg ±1 h ±1 sufentanil in combination with midazolam for analgesia and sedation of mechanically ventilated ICU patients and Hofbauer and colleagues 5 administered 0.75±1.0 mg kg ±1 h ±1 sufentanil combined with midazolam in ICU patients requiring mechanical ventilation for more than 96 h. Nevertheless, the scheduled initial dose in the present study proved suf®cient. In addition, in many cases the supplementary dose of 2 mg kg ±1 h ±1 propofol initially set in our study could even be reduced. Once adjusted by clinical assessment of pain, neither the dose of remifentanil or sufentanil had to be reduced in any of the patients during the 24 h observation period. This pattern suggests that neither remifentanil or sufentanil accumulated after a 24 h infusion period, although it has been demonstrated for sufentanil, that the context-sensitive half time increases continuously after 25 min of continuous infusion. 3 12 13 By contrast, Egan and colleagues 3 determined the context-sensitive half time for remifentanil to be 3±4 min, independent of the duration of infusion.
Patients in the remifentanil group required signi®cantly more propofol than patients in the sufentanil group. Therefore, it may be that the analgesic dosages used in our study were not equivalent and differences in the pharmacodynamic effects of remifentanil and sufentanil may be responsible for the different propofol requirements. Sufentanil has a greater hypnotic potency than other opiates, for example, morphine, fentanyl, alfentanil or remifentanil, and has been proven to be suitable as monoanaesthetic for analgesia and sedation in ICU patients. 7 8 14±16 As no patient complained of pain during continuous infusion of remifentanil, the higher dosage of propofol needed in this group is most probably a result of a less pronounced hypnotic potency of remifentanil, rather than an insuf®cient analgesic effect provided by the chosen dose of remifentanil. However, there surely exists a drug interaction between propofol and both opioids. So one must be aware of the dif®culty of separating the clinical effects of analgesia and sedation at such high levels of drug effect.
We observed pronounced differences between the groups with respect to time required for recovery. We assume that, even at the 10-min time point, a substantial sedative effect of propofol no longer existed in any patient because, in the remifentanil group, no sedative effect of propofol was present 10 min after terminating the infusion in spite of the higher propofol dose in this group. Therefore, we attribute the poorer recovery in the sufentanil group to the sedative effect of sufentanil.
In most patients on the ICU it would not be of particular advantage to decrease the emergence from analgesia and sedation to a few minutes. Thus, the use of an expensive analgesic drug like remifentanil may still remain the exception rather than the rule in the future. It might even be more comfortable for the patient to be treated with longer acting opioids as analgesia does not fade immediately after stopping their administration. This might be one of the reasons why morphine and fentanyl were recommended as the preferred analgesic agents for the critically ill by a consensus conference of 40 experts in 1995. 4 However, there are situations requiring regular neurological assessment by clinical signs and remifentamil may be advantageous in these cases. 17 In conclusion, the use of remifentanil combined with propofol up to 24 h postoperation provides adequate analgesia in patients with no intracranial pathology, after elective maxillo-facial surgery or severe trauma. A more rapid emergence from analgesia and sedation with remifentanil compared with sufentanil is indicative of the pharmacokinetic properties of remifentanil. Despite high cost and rapid termination of effect, the use of remifentanil may be particularly advantageous in patients suffering from severe intracranial disease or head trauma because it allows intermittent and rapid neurological assessment by clinical examination.
